This compound is a quinazoline-based derivative intended for use as an active pharmaceutical ingredient. It features a complex structure including multiple aromatic rings, ether linkages, and halogen substituents, and is typically supplied as a research-grade material for pharmaceutical manufacturing.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1680184-59-1
Rimonabant
pharmaceutical raw material
Oxymatrine
active pharmaceutical ingredient
2-Oxo Mirabegron
pharmaceutical raw material
Josamycin
pharmaceutical raw material
Afatinib, (R)-
pharmaceutical raw material
N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide
pharmaceutical raw material
Afatinib
pharmaceutical raw material
Afatinib dimaleate
pharmaceutical raw material
(Z)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide
ULXXDDBFHOBEHA-QGZUEGPWSA-N
CN(C)C/C=C\C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4